PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status

Glioblastoma has a dismal prognosis and molecular targeted agents have failed to improve outcomes to date. PARADIGM-2 is a phase I dose escalation study evaluating olaparib plus radiotherapy ± temozolomide in newly diagnosed glioblastoma, using MGMT methylation status to stratify patients and inform...

Descripción completa

Detalles Bibliográficos
Autores principales: Fulton, Ben, Short, Susan C., James, Allan, Nowicki, Stefan, McBain, Catherine, Jefferies, Sarah, Kelly, Caroline, Stobo, Jon, Morris, Anna, Williamson, Aoife, Chalmers, Anthony J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862667/
https://www.ncbi.nlm.nih.gov/pubmed/29594237
http://dx.doi.org/10.1016/j.ctro.2017.11.003
Descripción
Sumario:Glioblastoma has a dismal prognosis and molecular targeted agents have failed to improve outcomes to date. PARADIGM-2 is a phase I dose escalation study evaluating olaparib plus radiotherapy ± temozolomide in newly diagnosed glioblastoma, using MGMT methylation status to stratify patients and inform treatment schedules.

Ejemplares similares